220 related articles for article (PubMed ID: 22705363)
1. Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.
Zhang J; Abdallah CG; Wang J; Wan X; Liang C; Jiang L; Liu Y; Huang H; Hong X; Huang Q; Wu R; Xu C
Psychiatry Res; 2012 Dec; 200(2-3):126-32. PubMed ID: 22705363
[TBL] [Abstract][Full Text] [Related]
2. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.
Adler LE; Olincy A; Cawthra EM; McRae KA; Harris JG; Nagamoto HT; Waldo MC; Hall MH; Bowles A; Woodward L; Ross RG; Freedman R
Am J Psychiatry; 2004 Oct; 161(10):1822-8. PubMed ID: 15465979
[TBL] [Abstract][Full Text] [Related]
3. P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.
Oranje B; Aggernaes B; Rasmussen H; Ebdrup BH; Glenthøj BY
Schizophr Bull; 2013 Mar; 39(2):472-80. PubMed ID: 22241164
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.
Hong X; Chan RC; Zhuang X; Jiang T; Wan X; Wang J; Xiao B; Zhou H; Jiang L; Weng B
Schizophr Res; 2009 Mar; 108(1-3):151-7. PubMed ID: 19106034
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic effects on auditory sensory gating in schizophrenia patients.
Sánchez-Morla EM; Santos JL; Aparicio A; García-Jiménez MA; Villanueva C; Martínez-Vizcaíno V; Arango C
Eur Neuropsychopharmacol; 2009 Dec; 19(12):905-9. PubMed ID: 19833483
[TBL] [Abstract][Full Text] [Related]
6. P50 gating at acute and post-acute phases of first-episode schizophrenia.
Devrim-Uçok M; Keskin-Ergen HY; Uçok A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1952-6. PubMed ID: 18929611
[TBL] [Abstract][Full Text] [Related]
7. Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients.
Boutros NN; Brockhaus-Dumke A; Gjini K; Vedeniapin A; Elfakhani M; Burroughs S; Keshavan M
Schizophr Res; 2009 Sep; 113(2-3):339-46. PubMed ID: 19524407
[TBL] [Abstract][Full Text] [Related]
8. A model of anticholinergic activity of atypical antipsychotic medications.
Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
[TBL] [Abstract][Full Text] [Related]
9. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.
Csomor PA; Preller KH; Geyer MA; Studerus E; Huber T; Vollenweider FX
Neuropsychopharmacology; 2014 Sep; 39(10):2485-96. PubMed ID: 24801767
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.
Shayegan DK; Stahl SM
CNS Spectr; 2004 Oct; 9(10 Suppl 11):6-14. PubMed ID: 15475871
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
[TBL] [Abstract][Full Text] [Related]
12. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
13. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
Light GA; Geyer MA; Clementz BA; Cadenhead KS; Braff DL
Am J Psychiatry; 2000 May; 157(5):767-71. PubMed ID: 10784470
[TBL] [Abstract][Full Text] [Related]
14. Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.
Kishi T; Moriwaki M; Kitajima T; Kawashima K; Okochi T; Fukuo Y; Furukawa O; Naitoh H; Fujita K; Iwata N
Psychopharmacology (Berl); 2010 Apr; 209(2):185-90. PubMed ID: 20177883
[TBL] [Abstract][Full Text] [Related]
15. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
16. Prepulse inhibition of the startle reflex in schizophrenia remains stable with short-term quetiapine.
Molina V; López DE; Villa R; Pérez J; Martín C; Ballesteros A; Cardoso A; Sancho C
Eur Psychiatry; 2011; 26(5):271-5. PubMed ID: 20542668
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine effects on auditory sensory gating in schizophrenia.
Arango C; Summerfelt A; Buchanan RW
Am J Psychiatry; 2003 Nov; 160(11):2066-8. PubMed ID: 14594761
[TBL] [Abstract][Full Text] [Related]
19. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Hanssens L; L'Italien G; Loze JY; Marcus RN; Pans M; Kerselaers W
BMC Psychiatry; 2008 Dec; 8():95. PubMed ID: 19102734
[TBL] [Abstract][Full Text] [Related]
20. Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine.
Aggernaes B; Glenthoj BY; Ebdrup BH; Rasmussen H; Lublin H; Oranje B
Int J Neuropsychopharmacol; 2010 Nov; 13(10):1383-95. PubMed ID: 20633319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
